glp 1 shot names Market Overview: GLP-1 Agonists and the Obesity Market | Blog what are the names of

Medication adjustment may be necessary in some cases

Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status

Some individuals may present with nonspecific symptoms such as increased fatigue, confusion (particularly in older adults), or worsening glycemic control without classic urinary symptoms

Instead, this drug interrupts signalling that could affect appetite in parts of the central nervous system that are not behind the blood-brain barrier

Handling Injection Site Reactions the Right Way Starting a GLP-1 medication is often a big step, and it's normal to feel a mix of hope and uncertainty, especially when you notice changes in your skin